Molecular basis and management of gastrointestinal stromal tumors

Ulas D. Bayraktar, Soley Bayraktar, Caio M. Rocha-Lima

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Molecularly targeted agents have dramatically impacted the management of several cancers. Targeting KIT has led to a new treatment paradigm in gastrointestinal stromal tumors (GISTs). KIT is a cell surface receptor with tyrosine kinases that, upon binding of its ligand, stem cell factor, activates various signaling pathways. Imatinib and sunitinib, both tyrosine kinase inhibitors directed to KIT, were approved for first- and secondline treatment of metastatic and unresectable GISTs. In this article, we will review the molecular pathogenesis of GISTs followed by a discussion of imatinib and sunitinib's role in the treatment of GISTs. Finally, we will introduce novel therapeutic options for imatinib- and sunitinib-resistant GISTs.

Original languageEnglish
Pages (from-to)2726-2734
Number of pages9
JournalWorld Journal of Gastroenterology
Volume16
Issue number22
DOIs
StatePublished - Jun 1 2010

Fingerprint

Gastrointestinal Stromal Tumors
Protein-Tyrosine Kinases
Stem Cell Factor
Cell Surface Receptors
Ligands
Imatinib Mesylate
sunitinib
Neoplasms

Keywords

  • Gastrointestinal stromal tumor
  • Imatinib
  • KIT
  • Nilotinib
  • Sunitinib

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Molecular basis and management of gastrointestinal stromal tumors. / Bayraktar, Ulas D.; Bayraktar, Soley; Rocha-Lima, Caio M.

In: World Journal of Gastroenterology, Vol. 16, No. 22, 01.06.2010, p. 2726-2734.

Research output: Contribution to journalArticle

Bayraktar, Ulas D. ; Bayraktar, Soley ; Rocha-Lima, Caio M. / Molecular basis and management of gastrointestinal stromal tumors. In: World Journal of Gastroenterology. 2010 ; Vol. 16, No. 22. pp. 2726-2734.
@article{3cf6dbc344d846d8bc35d4756e6a9408,
title = "Molecular basis and management of gastrointestinal stromal tumors",
abstract = "Molecularly targeted agents have dramatically impacted the management of several cancers. Targeting KIT has led to a new treatment paradigm in gastrointestinal stromal tumors (GISTs). KIT is a cell surface receptor with tyrosine kinases that, upon binding of its ligand, stem cell factor, activates various signaling pathways. Imatinib and sunitinib, both tyrosine kinase inhibitors directed to KIT, were approved for first- and secondline treatment of metastatic and unresectable GISTs. In this article, we will review the molecular pathogenesis of GISTs followed by a discussion of imatinib and sunitinib's role in the treatment of GISTs. Finally, we will introduce novel therapeutic options for imatinib- and sunitinib-resistant GISTs.",
keywords = "Gastrointestinal stromal tumor, Imatinib, KIT, Nilotinib, Sunitinib",
author = "Bayraktar, {Ulas D.} and Soley Bayraktar and Rocha-Lima, {Caio M.}",
year = "2010",
month = "6",
day = "1",
doi = "10.3748/wjg.v16.i22.2726",
language = "English",
volume = "16",
pages = "2726--2734",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "22",

}

TY - JOUR

T1 - Molecular basis and management of gastrointestinal stromal tumors

AU - Bayraktar, Ulas D.

AU - Bayraktar, Soley

AU - Rocha-Lima, Caio M.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Molecularly targeted agents have dramatically impacted the management of several cancers. Targeting KIT has led to a new treatment paradigm in gastrointestinal stromal tumors (GISTs). KIT is a cell surface receptor with tyrosine kinases that, upon binding of its ligand, stem cell factor, activates various signaling pathways. Imatinib and sunitinib, both tyrosine kinase inhibitors directed to KIT, were approved for first- and secondline treatment of metastatic and unresectable GISTs. In this article, we will review the molecular pathogenesis of GISTs followed by a discussion of imatinib and sunitinib's role in the treatment of GISTs. Finally, we will introduce novel therapeutic options for imatinib- and sunitinib-resistant GISTs.

AB - Molecularly targeted agents have dramatically impacted the management of several cancers. Targeting KIT has led to a new treatment paradigm in gastrointestinal stromal tumors (GISTs). KIT is a cell surface receptor with tyrosine kinases that, upon binding of its ligand, stem cell factor, activates various signaling pathways. Imatinib and sunitinib, both tyrosine kinase inhibitors directed to KIT, were approved for first- and secondline treatment of metastatic and unresectable GISTs. In this article, we will review the molecular pathogenesis of GISTs followed by a discussion of imatinib and sunitinib's role in the treatment of GISTs. Finally, we will introduce novel therapeutic options for imatinib- and sunitinib-resistant GISTs.

KW - Gastrointestinal stromal tumor

KW - Imatinib

KW - KIT

KW - Nilotinib

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=77954269924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954269924&partnerID=8YFLogxK

U2 - 10.3748/wjg.v16.i22.2726

DO - 10.3748/wjg.v16.i22.2726

M3 - Article

C2 - 20533592

AN - SCOPUS:77954269924

VL - 16

SP - 2726

EP - 2734

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 22

ER -